Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002020963 | SCV002298240 | uncertain significance | COG7 congenital disorder of glycosylation | 2022-07-26 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 482 of the COG7 protein (p.Cys482Tyr). This variant is present in population databases (rs376426601, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with COG7-related conditions. ClinVar contains an entry for this variant (Variation ID: 1515260). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002020963 | SCV002776138 | uncertain significance | COG7 congenital disorder of glycosylation | 2022-01-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003348764 | SCV004067887 | uncertain significance | Inborn genetic diseases | 2023-06-29 | criteria provided, single submitter | clinical testing | The c.1445G>A (p.C482Y) alteration is located in exon 11 (coding exon 11) of the COG7 gene. This alteration results from a G to A substitution at nucleotide position 1445, causing the cysteine (C) at amino acid position 482 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |